Obese Patients With Type 2 Diabetes

Phase 3 Completed 1045 enrolled Sanofi

RandomizedParallel-groupDouble-blindTreatment

Summary

To assess the effect on weight loss and weight maintenance over a period of one year when prescribed with a hypocaloric diet in obese patients with Type 2 Diabetes

Timeline

Start: 2001-10
Primary completion: 2004-05
Completion: 2004-05

Outcome

Met primary endpoint

paper Weight loss was significantly greater after 1 year in both rimonabant groups than in the placebo group PMID 17098084 ↗

Publications

Results Scheen AJ, Finer N, Hollander P, Jensen MD, Van Gaal LF; RIO-Diabetes Study Group. Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study. Lancet. 2006 Nov 11;368(9548):1660-72. doi: 10.1016/S0140-6736(06)69571-8.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Rimonabant	Small molecule	5 mg	—
Subject	Rimonabant	Small molecule	20 mg	—